Skip to content
Evigrade
MajorAntiretroviral, HIV protease inhibitor×Antiplatelet agents – P2Y12 receptor inhibitors

Updated · Methodology

Mechanism

Clopidogrel is a prodrug: its active metabolite inhibits platelets. Liver cytochrome P450 enzymes form this metabolite, mainly CYP2C19, with contributions from CYP1A2, CYP2B6 and CYP3A4 (clopidogrel summary of product characteristics, SmPC, European Medicines Agency, EMA, section 5.2; Plavix prescribing information, US Food and Drug Administration, FDA, section 5.1). Atazanavir, and the ritonavir or cobicistat used to boost it, inhibit CYP3A4, so the antiplatelet effect of clopidogrel may weaken (atazanavir and atazanavir/cobicistat SmPCs, EMA, section 4.5). The US atazanavir label reports lower levels of the clopidogrel active metabolite (Reyataz prescribing information, FDA, section 7). In people with human immunodeficiency virus (HIV) on antiretroviral therapy boosted with ritonavir or cobicistat, platelet inhibition was significantly reduced. These patients already have a higher risk of vascular events (clopidogrel SmPC, EMA, section 4.5). The clinical relevance of this reduction is uncertain. However, there have been spontaneous reports of re-occlusion after revascularisation and of thrombotic events with a clopidogrel loading-dose regimen in people on ritonavir-boosted therapy (clopidogrel SmPC, EMA, section 4.5).

Symptoms

The documents describe no symptoms specific to this combination. The combination can weaken the antiplatelet effect of clopidogrel (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA, section 4.5). With ritonavir-boosted antiretroviral therapy, re-occlusion after revascularisation and thrombotic events have been reported (clopidogrel SmPC, EMA, section 4.5). The most common adverse effect of clopidogrel itself is bleeding, reported mostly in the first month of treatment. Atazanavir commonly causes nausea, diarrhoea and jaundice (clopidogrel and atazanavir SmPCs, EMA, section 4.8).

Management

The combination is not recommended. The atazanavir labels name clopidogrel explicitly for the ritonavir-boosted regimen, for the cobicistat-boosted regimen and for unboosted atazanavir (atazanavir and atazanavir/cobicistat summaries of product characteristics, SmPC, European Medicines Agency, EMA, section 4.5; Reyataz prescribing information, US Food and Drug Administration, FDA, section 7). The clopidogrel SmPC also advises against combining clopidogrel with antiretroviral therapy boosted with ritonavir or cobicistat (clopidogrel SmPC, EMA, section 4.5). Instead of clopidogrel, an antiplatelet drug not affected by inhibition or induction of cytochrome P450 (CYP) enzymes, such as prasugrel, is recommended (atazanavir/cobicistat SmPC, EMA, section 4.5). No prasugrel dose adjustment is needed with atazanavir, with or without ritonavir (atazanavir SmPC, EMA, section 4.5). Ticagrelor is not an alternative: it is not recommended with atazanavir and is contraindicated with atazanavir plus cobicistat (atazanavir and atazanavir/cobicistat SmPCs, EMA, sections 4.3 and 4.5). Stopping clopidogrel increases the risk of cardiovascular events. After a necessary interruption, it is restarted as soon as possible (Plavix prescribing information, FDA, section 5.3).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Atazanavir

Other interactions with Clopidogrel